FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Senate Letter Presses HHS on Foreign Generic Drugs

[ Price : $8.95]

A Senate Committee demands answers from HHS on what they describe as serious national security and public health risks tied to Ame...

BridgeBio Plans NDA for Muscular Dystrophy Therapy

[ Price : $8.95]

BridgeBio reports positive Phase 3 data for BBP-418 in limb-girdle muscular dystrophy patients as it plans an NDA filing in second...

Guide on Device Quality Management Submission Info

[ Price : $8.95]

FDA releases a draft guidance outlining recommendations for medical device manufacturers on the type of Quality Management System ...

Hetero Labs India Warehouse Cited After Inspection

[ Price : $8.95]

FDA posts a six-item Form FDA-483 after inspecting Hetero Labs Vishakapatnam, India, warehouse last month.

FDA Expands Mercks Winrevair Label

[ Price : $8.95]

FDA approves an expanded indication for Mercks pulmonary arterial hypertension therapy Winrevair (sotatercept-csrk), clearing the ...

YorLabs Novel Intracardiac Imaging System Cleared

[ Price : $8.95]

FDA clears a YorLabs 510(k) for its new intracardiac imaging system that the company says could reshape workflows in catheterizati...

Sydnexis Hit with FDA Rejection for Myopia Drug

[ Price : $8.95]

FDA sends Sydnexis a complete response letter for SYD-101, a low-dose atropine eye-drop candidate intended to slow disease progres...

FDA Breakthrough for NRG1+ Cholangiocarcinoma Drug

[ Price : $8.95]

FDA grants Partner Therapeutics a breakthrough therapy designation for zenocutuzumab-zbco and its use in treating cholangiocarcino...

Inhibrx Posts Positive Phase 3 Results for Ozekibart

[ Price : $8.95]

Inhibrx Biosciences reports favorable data for treating chondrosarcoma with its antibody therapy ozekibart (INBRX-109).

Sumitomo Pharma Gets FDA-483 After Inspection

[ Price : $8.95]

FDA posts a two-item Form FDA-483 from an August inspection of Sumitomo Pharmas Suzuka, Japan, manufacturing facility.